Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
NCT ID: NCT06212648
Last Updated: 2024-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
253 participants
INTERVENTIONAL
2022-03-25
2023-01-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
NCT06826872
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
NCT07064525
Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
NCT02651870
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
NCT02944734
A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
NCT05450601
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects who meet the selection and exclusion criteria should take a placebo for 2 weeks during the run-in period and run a lifestyle improvement program in parallel.
However, if you are already taking antihypertensive drugs at the time of screening, you should stop taking your existing antihypertensive drugs for at least 4 weeks from before the run-in period to the time of randomization to avoid affecting the clinical trial results.
Subjects who meet the final selection and exclusion criteria at the end of the run-in period are randomly assigned 1:1:1:1:1:1:1:1 to each administration group, receive a prescription for clinical trial drugs, and administer for 8 weeks in a double-blind manner.
Encourage the subjects to continuously perform the lifestyle improvement program for 8 weeks during the administration of the clinical investigational drug and visit the testing institution at 4 and 8 weeks during the 8-week trial period, excluding randomized visits, to check the efficacy and safety.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SPC1001 High
SPC1001 High (Candesartan/Amlodipine/Indapamide)
SPC1001 High
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Placebo
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC1001 Mid1
SPC1001 Mid1 (Candesartan/Amlodipine/Indapamide)
SPC1001 Mid1
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Placebo
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC1001 Mid2
SPC1001 Mid1 (Candesartan/Amlodipine/Indapamide)
SPC1001 Mid2
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Placebo
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC1001 Low
SPC1001 Low (Candesartan/Amlodipine/Indapamide)
SPC1001 Low
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Placebo
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC3001
SPC3001 (Candesartan 8mg)
SPC3001
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Placebo
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC4001
SPC4001 (Amlodipine 5mg)
SPC4001
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Placebo
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC4002
SPC4002 (Amlodipine 10mg)
SPC4002
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Placebo
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Placebo
SPC1001(High, Mid1, Mid2, Low) placebo, SPC3001 placebo, SPC4001 placebo, SPC4002 placebo
Placebo
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SPC1001 High
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC1001 Mid1
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC1001 Mid2
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC1001 Low
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC3001
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC4001
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC4002
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Placebo
Drugs for clinical trials are orally administered once a day after breakfast.
After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Those whose blood pressure measured at the time of screening meets the following criteria 2.1 Not taking antihypertensive drugs (Naïve): 140 mmHg ≤ MSSBP (mean sitting SBP) \< 180 mmHg 2.2 If you are taking antihypertensive drugs or have diabetes or chronic kidney disease: 130 mmHg ≤ MSSBP \< 180 mmHg
3. Those whose blood pressure measured at the time of randomization meets the following criteria 3.1. 140 mmHg ≤ MSSBP \< 180 mmHg 3.2. Or patients with diabetes or chronic kidney disease 130 mmHg ≤ MSSBP \< 180 mmHg (However, patients with chronic kidney disease who have clinically significant albuminuria or proteinuria within 6 months)
4. Those who voluntarily agreed to participate in this clinical trial and signed the consent form
Exclusion Criteria
2. Patients who showed a difference of SBP 20 mmHg or more and DBP 10 mmHg or more in blood pressure measured 3 times in both arms at screening
3. Patients with a history of secondary hypertension or any history of suspected secondary hypertension (aortic stenosis, primary hyperaldosteronemia, renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc.)
4. Patients with symptomatic orthostatic hypotension
5. Patients requiring concomitant administration of other antihypertensive drugs in addition to investigational drugs during clinical trial participation (Diuretics, β-blockers, ACE inhibitors, Angiotensin II Receptor Blocker, Calcium Channel Blockers, α-blockers, Renin Inhibitors, Vasodilators, etc.)
6. Patients with the following past medical history/comorbidities at the screening visit 6.1. Uncontrolled diabetic patients with HbA1c ≥ 9% 6.2. Patients with severe heart disease (heart failure (NYHA class 3 and 4)), ischemic heart disease (unstable angina, acute myocardial infarction) within 6 months of screening, peripheral vascular disease, percutaneous coronary angioplasty or coronary artery bypass surgery ruler) 6.3. Patients with clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter, or other arrhythmias determined by the investigator to be clinically significant 6.4. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, hemodynamically significant aortic stenosis, stenosis on the aortic or mitral valve 6.5. Patients with the severe cerebrovascular disorder (stroke, cerebral infarction, cerebral hemorrhage, etc. within 6 months of screening) 6.6. Patients with known moderate or malignant retinopathy (retinal hemorrhage within 6 months of screening, visual impairment, retinal microaneurysm) 6.7. Patients with wasting disease, autoimmune disease, connective tissue disease 6.8. Patients with gastrointestinal diseases and surgeries that may affect drug absorption, distribution, metabolism, and excretion, current active gastritis, gastrointestinal/rectal bleeding, gastric ulcer, pancreatic dysfunction such as pancreatitis, active inflammatory bowel syndrome within 12 months of screening Back (However, simple appendectomy and hernia surgery are excluded) 6.9. Patients with hereditary angioedema or with a history of angioedema when treated with ACE inhibitors, renin inhibitors, or angiotensin II receptor antagonists 6.10. cholestatic disease patient 6.11. shock patient 6.12. Patients with anuria 6.13. Patients with symptomatic hyperuricemia (history of gout or uric acid stones) 6.14. Patients with a history of malignant tumors including leukemia and lymphoma within 5 years of screening (however, those who have been evaluated as having complete response after treatment and have not relapsed within 2 years of screening, or malignant tumors that have occurred are the only Those with basal cell carcinoma or squamous cell carcinoma of the skin can participate in this test) 6.15. Patients with any chronic inflammatory condition requiring chronic anti-inflammatory treatment
7. Persons whose laboratory test results at the screening visit fall under the following 7.1. Those whose ALT or AST levels are more than 3 times the upper limit of normal organ 7.2. Those whose serum creatinine level is 1.5 times or more of the upper limit of normal organ 7.3. Patients with renal impairment with severe renal failure with Creatinine Clearance (CrCl) \< 30 mL/min or eGFR \< 30 ml/min/1.73 m2 7.4. Hypokalemia (Serum K \< 3.5 mmol/L) 7.5. Persons with hyperkalemia (Serum K \> 5.5 mmol/L) 7.6. Those with hyponatremia (Serum Na \< 135.0 mmol/L) 7.7. Those with hypercalcemia (Serum Ca \> 2.75 mmol/L or 11 mg/dL)
8. Those with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
9. Persons with or suspected of drug or alcohol abuse
10. Pregnant or lactating women
11. Women and men of childbearing potential who do not agree to use a combination of effective or medically acceptable contraceptive methods\* for the duration of the clinical trial and 4 weeks after administration of the last investigational drug
\* Taking birth control pills or implanting hormones, implanting intrauterine devices or intrauterine systems, double-blocking methods (both male (condom) and female (contraceptive diaphragm, vaginal sponge or cervical cap) using a contraceptive device), sterilization ( vasectomy, tubal ligation, etc.)
12. Persons with a history of hypersensitivity to clinical investigational drug components and other dihydropyridine drugs, thiazide drugs, or sulfonamide derivatives
13. Those who participated in another clinical trial within 4 weeks before the screening visit and received the investigational drug
14. Others who are judged to be unable to participate in clinical trials cording to the judgment of the investigator
19 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shin Poong Pharmaceutical Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHA Gangnam Medical Center, CHA University
Seoul, Gangnam, South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shin J, Kim S, Han K, Kim M, Ahn Y, Sohn I, Kim K, Cha D, Hong S, Cho E, Lee H, Pyun W, Youn H, Kim W, Rhee M, Lee J, Ha J, Choi J, Yoo B, Jeong J, Chung W, Jeong Y, Kim C. Multicenter, Randomized, Double-Blind, Parallel, Phase 2 Clinical Trial to Compare and Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension. Clin Ther. 2025 Oct 28:S0149-2918(25)00347-9. doi: 10.1016/j.clinthera.2025.10.001. Online ahead of print.
Related Links
Access external resources that provide additional context or updates about the study.
From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century
When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP-CAP-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.